Mission Statement, Vision, & Core Values of Iterum Therapeutics plc (ITRM)

What drives a company like Iterum Therapeutics (ITRM), especially in the challenging field of combating multi-drug resistant pathogens? Understanding their mission, vision, and core values provides insight into their strategic direction and commitment to innovation. With a focus on next-generation oral and IV antibiotics, and the recent FDA approval of ORLYNVAH™ for uncomplicated urinary tract infections (uUTIs), how do these guiding principles shape their approach to addressing global health crises and impacting the lives of those affected by serious diseases?

Iterum Therapeutics, which ended 2024 with $24.1 million in cash and cash equivalents, is focused on delivering differentiated anti-infectives. The company's R&D expenses decreased to $10.5 million in 2024 from $40.0 million in 2023, while G&A expenses increased to $8.0 million from $7.5 million in the same period. Their net loss for 2024 improved to $24.8 million from $38.4 million in 2023. Let's explore the mission, vision, and core values that steer Iterum Therapeutics toward its goals.

Iterum Therapeutics plc (ITRM) An Overview of

Iterum Therapeutics plc, is a pharmaceutical company focused on developing and commercializing anti-infectives to fight the global rise of multi-drug resistant pathogens. The company's primary product is sulopenem, a novel anti-infective compound. Sulopenem is intended to provide a targeted approach to combat infections caused by multi-drug resistant bacteria in both the hospital and community settings. As of April 2025, Iterum Therapeutics continues to focus on securing regulatory approvals and establishing commercial partnerships to bring sulopenem to market.

While specific, up-to-the-minute sales figures for April 2025 are not available, it is important to consider Iterum's recent financial performance to understand its current standing. Recent financial reports highlight key aspects of the company's performance:

• Revenue: Although the company has been focused on development, regulatory approval, and preparing for the commercial launch of Sulopenem, revenue generation has been limited until product sales commence.
• Operating Expenses: Operating expenses, including research and development (R&D) and general and administrative (G&A) costs, are significant due to ongoing clinical trials and regulatory efforts.
• Net Loss: As is typical for development-stage pharmaceutical companies, Iterum Therapeutics has experienced net losses as it invests heavily in its pipeline.
• Liquidity: Maintaining sufficient liquidity is crucial. The company actively manages its cash reserves and explores financing options to support its operations.

Iterum Therapeutics is positioning itself as a key player in the fight against antibiotic resistance. To delve deeper into the company's background, mission, and operational strategies, check out this comprehensive resource: Iterum Therapeutics plc (ITRM): History, Ownership, Mission, How It Works & Makes Money.

Iterum Therapeutics plc (ITRM) Mission Statement

Iterum Therapeutics plc, a pharmaceutical company, focuses on developing and commercializing anti-infectives to treat multi-drug resistant organisms. While a specific, publicly declared mission statement for Iterum Therapeutics plc isn't readily available, we can infer their mission from their activities and focus. Their work suggests a mission centered around addressing unmet needs in infectious disease treatment, particularly those caused by multi-drug resistant organisms, and improving patient outcomes. This implied mission emphasizes innovation, scientific rigor, and a commitment to global health.

Understanding a company's mission requires looking at its core objectives and actions. Here are key components that likely underpin Iterum Therapeutics' mission:

• Focus on Unmet Needs: Addressing the challenge of multi-drug resistant infections, where existing treatments are inadequate.
• Innovation in Anti-Infectives: Developing new and effective anti-infective therapies to combat resistant bacteria.
• Improving Patient Outcomes: Enhancing treatment options and results for patients suffering from severe infections.
• Scientific Rigor: Maintaining high standards in research, development, and clinical trials to ensure product safety and efficacy.
• Global Health Commitment: Contributing to the global effort to combat antibiotic resistance and infectious diseases.

To gain more insights into Iterum Therapeutics and its investors, check out this resource: Exploring Iterum Therapeutics plc (ITRM) Investor Profile: Who’s Buying and Why?

Iterum Therapeutics plc (ITRM) Vision Statement of

Iterum Therapeutics plc, a pharmaceutical company focused on developing and commercializing anti-infectives to fight the global rise of multi-drug resistant infections, articulates its strategic direction through its mission statement, vision, and core values. These elements collectively define the company's purpose, desired future state, and guiding principles.

As of April 2025, while a comprehensive updated vision statement for Iterum Therapeutics plc is not explicitly available, we can infer aspects of their vision from their publicly stated goals, actions, and values. Their primary focus remains on combating multi-drug resistant infections, particularly in the context of complicated and uncomplicated urinary tract infections.

Combating Multi-Drug Resistance

Iterum Therapeutics' core focus is on addressing the challenge of multi-drug resistant infections. This is evident in their development of sulopenem, a potent penem anti-infective. Their vision involves:

• Developing and commercializing sulopenem to provide a therapeutic option for infections caused by multi-drug resistant bacteria.
• Reducing the overuse of broad-spectrum antibiotics, which contribute to the development of resistance.
• Establishing sulopenem as a first-line treatment option in specific infectious disease scenarios.

Focus on Sulopenem

Sulopenem is central to Iterum Therapeutics' vision. Their efforts concentrate on:

• Gaining regulatory approval for sulopenem from agencies like the FDA.
• Successfully launching and marketing sulopenem in the U.S. and potentially other global markets.
• Expanding the potential uses of sulopenem through further clinical trials and research.

Strategic Partnerships and Growth

Iterum Therapeutics' vision also incorporates strategic collaborations and business development to support their goals:

• Seeking partnerships to expand the commercial reach of sulopenem.
• Exploring opportunities to in-license or acquire other complementary assets in the anti-infectives space.
• Ensuring sustainable growth and value creation for shareholders.

Financial Stability and Market Presence

A key aspect of Iterum's vision is to achieve financial stability and establish a strong market presence. This includes:

• Securing funding to support ongoing operations and clinical development. For instance, in 2024, Iterum announced a \$40 million private placement financing.
• Managing debt and optimizing capital structure. In 2024, the company successfully reduced its debt by \$24 million.
• Building a robust commercial infrastructure to support the launch of sulopenem.

In summary, Iterum Therapeutics' vision as of April 2025 centers on becoming a key player in the fight against multi-drug resistant infections, primarily through the development and commercialization of sulopenem. This involves strategic execution across regulatory, commercial, and financial fronts, with the ultimate goal of delivering value to patients and shareholders.

Iterum Therapeutics plc (ITRM) Core Values of

As of April 2025, while specific, formally declared core values for Iterum Therapeutics plc (ITRM) may not be explicitly available in the same manner as some larger corporations, the company's actions, statements, and strategic priorities reveal a set of underlying principles that guide its operations. These inferred values emphasize innovation, patient focus, integrity, and collaboration.

Innovation

Innovation is crucial for Iterum Therapeutics as it operates in the highly competitive pharmaceutical industry. The company focuses on developing and commercializing novel anti-infectives to combat the growing threat of multi-drug resistant organisms. This commitment is evident in their lead product, sulopenem, and their efforts to gain regulatory approval and bring it to market. Innovation is not just about creating new drugs but also about finding better ways to address unmet medical needs.

Examples of Iterum's commitment to innovation:

• Sulopenem Development: The development of sulopenem showcases Iterum's dedication to creating innovative solutions for antibiotic-resistant infections.
• Clinical Trials: Conducting thorough clinical trials to ensure the efficacy and safety of their products.

Patient Focus

A patient-centric approach is fundamental to Iterum Therapeutics. Their work aims to provide effective treatments for infections, improving patient outcomes and quality of life. This focus is demonstrated through their commitment to addressing unmet needs in the treatment of multi-drug resistant infections, which directly impacts patient health.

Examples of Iterum's commitment to patient focus:

• Addressing Unmet Needs: Focusing on infections with limited treatment options to improve patient care.
• Ensuring Safety and Efficacy: Prioritizing patient safety and drug effectiveness through rigorous testing and monitoring.

Integrity

Integrity is essential in all aspects of Iterum Therapeutics' operations. This includes adherence to ethical standards in research, development, and commercialization. Transparency and accountability in their interactions with healthcare professionals, regulatory bodies, and the public build trust and credibility.

Examples of Iterum's commitment to integrity:

• Ethical Research Practices: Conducting research and development with the highest ethical standards.
• Regulatory Compliance: Adhering to all regulatory requirements and guidelines.

Collaboration

Collaboration is key to Iterum Therapeutics' success. By working with researchers, healthcare providers, and other stakeholders, they can leverage diverse expertise and resources to advance their mission. This collaborative approach is evident in their partnerships and interactions within the medical and scientific community.

Examples of Iterum's commitment to collaboration:

• Partnerships: Collaborating with other organizations to enhance research and development efforts.
• Community Engagement: Engaging with the medical and scientific community to share knowledge and advance treatment options.

To gain more insights into Iterum Therapeutics' financial stability and strategic moves, explore this comprehensive analysis: Breaking Down Iterum Therapeutics plc (ITRM) Financial Health: Key Insights for Investors